

# Laura Calabresi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/20594/laura-calabresi-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

174  
papers

6,156  
citations

44  
h-index

71  
g-index

182  
ext. papers

6,910  
ext. citations

5.4  
avg, IF

5.39  
L-index

#	Paper	IF	Citations
174	Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders.. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2022</b> , 1867, 159123	5	1
173	Plasma fatty acid composition in familial LCAT deficiency indicates SOAT2-derived cholesteryl ester formation in humans. <i>Journal of Lipid Research</i> , <b>2022</b> , 100232	6.3	
172	Abdominal obesity negatively influences key metrics of reverse cholesterol transport. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2021</b> , 1867, 159087	5	0
171	The HDL mimetic CER-001 remodels plasma lipoproteins and reduces kidney lipid deposits in inherited lecithin:cholesterol acyltransferase deficiency. <i>Journal of Internal Medicine</i> , <b>2021</b> ,	10.8	2
170	High-Density Lipoproteins and the Kidney. <i>Cells</i> , <b>2021</b> , 10,	7.9	2
169	Intracoronary monocyte expression pattern and HDL subfractions after non-ST elevation myocardial infarction. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2021</b> , 1867, 166116	6.9	
168	CER-001 ameliorates lipid profile and kidney disease in a mouse model of familial LCAT deficiency. <i>Metabolism: Clinical and Experimental</i> , <b>2021</b> , 116, 154464	12.7	3
167	Vasculoprotective properties of plasma lipoproteins from brown bears ( <i>Ursus arctos</i> ). <i>Journal of Lipid Research</i> , <b>2021</b> , 62, 100065	6.3	1
166	Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination ( BB536, Red Yeast Rice Extract) (Randomized, Double-Blind, Placebo-Controlled Study). <i>Nutrients</i> , <b>2021</b> , 13,	6.7	4
165	LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters. <i>Atherosclerosis</i> , <b>2020</b> , 297, 8-15	3.1	4
164	Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 27, 1639-1646	3.9	8
163	Progression of chronic kidney disease in familial LCAT deficiency: a follow-up of the Italian cohort. <i>Journal of Lipid Research</i> , <b>2020</b> , 61, 1784-1788	6.3	10
162	Activation of Naturally Occurring Lecithin:Cholesterol Acyltransferase Mutants by a Novel Activator Compound. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2020</b> , 375, 463-468	4.7	6
161	Genetic, biochemical, and clinical features of LCAT deficiency: update for 2020. <i>Current Opinion in Lipidology</i> , <b>2020</b> , 31, 232-237	4.4	21
160	Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney Disease. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	10
159	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Biomedicines</i> , <b>2020</b> , 8,	4.8	4
158	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 50-67	18.1	48

157	rHDL modeling and the anchoring mechanism of LCAT activation. <i>Journal of Lipid Research</i> , <b>2020</b> , 62, 100006	6.3	2
156	Recombinant LCAT (Lecithin:Cholesterol Acyltransferase) Rescues Defective HDL (High-Density Lipoprotein)-Mediated Endothelial Protection in Acute Coronary Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2019</b> , 39, 915-924	9.4	24
155	Nutraceutical approach for the management of cardiovascular risk - a combination containing the probiotic <i>Bifidobacterium longum</i> BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study. <i>Nutrition Journal</i> , <b>2019</b> , 18, 13	4.3	23
154	Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels. <i>Journal of Clinical Lipidology</i> , <b>2019</b> , 13, 778-787.e6	4.9	11
153	The Extent of Human Apolipoprotein A-I Lipidation Strongly Affects the $\beta$ Amyloid Efflux Across the Blood-Brain Barrier. <i>Frontiers in Neuroscience</i> , <b>2019</b> , 13, 419	5.1	31
152	Dysfunctional HDL as a Therapeutic Target for Atherosclerosis Prevention. <i>Current Medicinal Chemistry</i> , <b>2019</b> , 26, 1610-1630	4.3	16
151	A proteomic approach to identify novel disease biomarkers in LCAT deficiency. <i>Journal of Proteomics</i> , <b>2019</b> , 198, 113-118	3.9	4
150	High Density Lipoproteins Inhibit Oxidative Stress-Induced Prostate Cancer Cell Proliferation. <i>Scientific Reports</i> , <b>2018</b> , 8, 2236	4.9	18
149	Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 279-288	15.1	30
148	Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial. <i>European Journal of Nutrition</i> , <b>2018</b> , 57, 499-511	5.2	33
147	Complete and Partial Lecithin:Cholesterol Acyltransferase Deficiency Is Differentially Associated With Atherosclerosis. <i>Circulation</i> , <b>2018</b> , 138, 1000-1007	16.7	35
146	Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2018</b> , 1863, 991-997	5	9
145	Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. <i>Advances in Therapy</i> , <b>2017</b> , 34, 1200-1210	4.1	39
144	Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency. <i>Journal of Lipid Research</i> , <b>2017</b> , 58, 994-1001	6.3	10
143	Lecithin:Cholesterol Acyltransferase Activation by Sulfhydryl-Reactive Small Molecules: Role of Cysteine-31. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2017</b> , 362, 306-318	4.7	21
142	Plasma cholesterol homeostasis, HDL remodeling and function during the acute phase reaction. <i>Journal of Lipid Research</i> , <b>2017</b> , 58, 2051-2060	6.3	26
141	Effects of a lupin protein concentrate on lipids, blood pressure and insulin resistance in moderately dyslipidaemic patients: A randomised controlled trial. <i>Journal of Functional Foods</i> , <b>2017</b> , 37, 8-15	5.1	13
140	Nutraceutical approaches to metabolic syndrome. <i>Annals of Medicine</i> , <b>2017</b> , 49, 678-697	1.5	18

139	Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients. <i>Atherosclerosis</i> , <b>2016</b> , 255, 17-24	3.1	23
138	Role of LCAT in Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , <b>2016</b> , 23, 119-27	4	39
137	Plasma-derived and synthetic high-density lipoprotein inhibit tissue factor in endothelial cells and monocytes. <i>Biochemical Journal</i> , <b>2016</b> , 473, 211-9	3.8	9
136	Lipoprotein X Causes Renal Disease in LCAT Deficiency. <i>PLoS ONE</i> , <b>2016</b> , 11, e0150083	3.7	43
135	Protective Effects of HDL Against Ischemia/Reperfusion Injury. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 2	5.6	16
134	High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis. <i>Endocrinology and Metabolism</i> , <b>2016</b> , 31, 223-9	3.5	31
133	Lupin protein exerts cholesterol-lowering effects targeting PCSK9: From clinical evidences to elucidation of the in vitro molecular mechanism using HepG2 cells. <i>Journal of Functional Foods</i> , <b>2016</b> , 23, 230-240	5.1	23
132	Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome. <i>Vascular Pharmacology</i> , <b>2015</b> , 74, 80-86	5.9	6
131	Structure of HDL: particle subclasses and molecular components. <i>Handbook of Experimental Pharmacology</i> , <b>2015</b> , 224, 3-51	3.2	130
130	Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention. <i>Journal of Clinical Lipidology</i> , <b>2015</b> , 9, 226-33	4.9	17
129	Cholesterol trafficking-related serum lipoprotein functions in children with cholesteryl ester storage disease. <i>Atherosclerosis</i> , <b>2015</b> , 242, 443-9	3.1	14
128	Acquired lecithin:cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease. <i>Journal of Internal Medicine</i> , <b>2015</b> , 277, 552-61	10.8	44
127	Beta2-adrenergic activity modulates vascular tone regulation in lecithin:cholesterol acyltransferase knockout mice. <i>Vascular Pharmacology</i> , <b>2015</b> , 74, 114-121	5.9	14
126	HDL and atherosclerosis: Insights from inherited HDL disorders. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2015</b> , 1851, 13-8	5	42
125	Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A case-control study. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2015</b> , 22, 187-93	2.7	3
124	A complex phenotype in a child with familial HDL deficiency due to a novel frameshift mutation in APOA1 gene (apoA-IGuastalla). <i>Journal of Clinical Lipidology</i> , <b>2015</b> , 9, 837-846	4.9	6
123	Familial LCAT deficiency: from pathology to enzyme replacement therapy. <i>Clinical Lipidology</i> , <b>2015</b> , 10, 405-413		4
122	Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function. <i>Handbook of Experimental Pharmacology</i> , <b>2015</b> , 224, 593-615	3.2	17

121	Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus. <i>Journal of Clinical Lipidology</i> , <b>2014</b> , 8, 61-8	4.9	61
120	HDL and cholesterol handling in the brain. <i>Cardiovascular Research</i> , <b>2014</b> , 103, 405-13	9.9	116
119	Lecithin:Cholesterol Acyltransferase (LCAT) Deficiency: Molecular Genetics <b>2014</b> ,		1
118	Hepatic ACAT2 knock down increases ABCA1 and modifies HDL metabolism in mice. <i>PLoS ONE</i> , <b>2014</b> , 9, e93552	3.7	20
117	Distant homology modeling of LCAT and its validation through in silico targeting and in vitro and in vivo assays. <i>PLoS ONE</i> , <b>2014</b> , 9, e95044	3.7	6
116	eNOS activation by HDL is impaired in genetic CETP deficiency. <i>PLoS ONE</i> , <b>2014</b> , 9, e95925	3.7	30
115	Genetic determinants of HDL metabolism. <i>Current Medicinal Chemistry</i> , <b>2014</b> , 21, 2855-63	4.3	1
114	Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. <i>Journal of Clinical Lipidology</i> , <b>2013</b> , 7, 414-22	4.9	31
113	Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome. <i>Cardiovascular Research</i> , <b>2013</b> , 100, 36-43	9.9	39
112	Recombinant human LCAT normalizes plasma lipoprotein profile in LCAT deficiency. <i>Biologicals</i> , <b>2013</b> , 41, 446-9	1.8	25
111	Off-target effects of thrombolytic drugs: apolipoprotein A-I proteolysis by alteplase and tenecteplase. <i>Biochemical Pharmacology</i> , <b>2013</b> , 85, 525-30	6	8
110	A proteomic portrait of atherosclerosis. <i>Journal of Proteomics</i> , <b>2013</b> , 82, 92-112	3.9	12
109	HDL and endothelial protection: examining evidence from HDL inherited disorders. <i>Clinical Lipidology</i> , <b>2013</b> , 8, 361-370		3
108	Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys. <i>Journal of Lipid Research</i> , <b>2013</b> , 54, 2341-53	6.3	25
107	Lipoprotein glomerulopathy associated with a mutation in apolipoprotein e. <i>Clinical Medicine Insights: Case Reports</i> , <b>2013</b> , 6, 189-96	0.8	7
106	Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease. <i>Atherosclerosis</i> , <b>2012</b> , 222, 299-306	3.1	87
105	Novel missense variants in LCAT and APOB genes in an Italian kindred with familial lecithin:cholesterol acyltransferase deficiency and hypobetalipoproteinemia. <i>Journal of Clinical Lipidology</i> , <b>2012</b> , 6, 244-50	4.9	5
104	A woman with low HDL cholesterol and corneal opacity. <i>Internal and Emergency Medicine</i> , <b>2012</b> , 7, 533-7	3.7	4

103	Hypocholesterolaemic effects of lupin protein and pea protein/fibre combinations in moderately hypercholesterolaemic individuals. <i>British Journal of Nutrition</i> , <b>2012</b> , 107, 1176-83	3.6	64
102	Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3. <i>Circulation: Cardiovascular Genetics</i> , <b>2012</b> , 5, 42-50		89
101	Severe high-density lipoprotein deficiency associated with autoantibodies against lecithin:cholesterol acyltransferase in non-Hodgkin lymphoma. <i>Archives of Internal Medicine</i> , <b>2012</b> , 172, 179-81		12
100	Lipid and apoprotein composition of HDL in partial or complete CETP deficiency. <i>Current Vascular Pharmacology</i> , <b>2012</b> , 10, 422-31	3.3	6
99	Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations. <i>Clinica Chimica Acta</i> , <b>2011</b> , 412, 1262-5	6.2	14
98	HDL, Reverse Cholesterol Transport, and Atherosclerosis <b>2011</b> , 159-165		
97	Native LDL-induced oxidative stress in human proximal tubular cells: multiple players involved. <i>Journal of Cellular and Molecular Medicine</i> , <b>2011</b> , 15, 375-95	5.6	8
96	Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk. <i>Journal of Lipid Research</i> , <b>2011</b> , 52, 1569-74	6.3	41
95	Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2011</b> , 31, 74-80	9.4	53
94	Conformation of dimeric apolipoprotein A-I milano on recombinant lipoprotein particles. <i>Biochemistry</i> , <b>2010</b> , 49, 5213-24	3.2	15
93	Structure and function of the apoA-IV T347S and Q360H common variants. <i>Biochemical and Biophysical Research Communications</i> , <b>2010</b> , 393, 126-30	3.4	12
92	Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. <i>Cell Metabolism</i> , <b>2010</b> , 12, 187-93	24.6	132
91	Paradoxical decrease in high-density lipoprotein cholesterol with fenofibrate: a quite rare phenomenon indeed. <i>Cardiovascular Therapeutics</i> , <b>2010</b> , 28, 153-60	3.3	6
90	High-density lipoprotein quantity or quality for cardiovascular prevention?. <i>Current Pharmaceutical Design</i> , <b>2010</b> , 16, 1494-503	3.3	28
89	Structural and dynamic features of apolipoprotein A-I cysteine mutants, Milano and Paris, in synthetic HDL. <i>Journal of Molecular Graphics and Modelling</i> , <b>2010</b> , 29, 406-14	2.8	6
88	Lecithin:cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans. <i>Trends in Cardiovascular Medicine</i> , <b>2010</b> , 20, 50-3	6.9	66
87	Genetic LCAT Deficiency: Molecular Diagnosis, Plasma Lipids, and Atherosclerosis <b>2010</b> , 89-93		1
86	Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans. <i>Circulation</i> , <b>2009</b> , 1	16.7	82

85	Structural features and dynamics properties of human apolipoprotein A-I in a model of synthetic HDL. <i>Journal of Molecular Graphics and Modelling</i> , <b>2009</b> , 28, 305-12	2.8	8
84	Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. <i>Biochemistry</i> , <b>2009</b> , 48, 11067-74	3.2	106
83	The plasma concentration of Lpa-I:A-II particles as a predictor of the inflammatory response in patients with ST-elevation myocardial infarction. <i>Atherosclerosis</i> , <b>2009</b> , 202, 304-11	3.1	14
82	Novel mutations of CETP gene in Italian subjects with hyperalphalipoproteinemia. <i>Atherosclerosis</i> , <b>2009</b> , 204, 202-7	3.1	24
81	Functional LCAT is not required for macrophage cholesterol efflux to human serum. <i>Atherosclerosis</i> , <b>2009</b> , 204, 141-6	3.1	62
80	A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred. <i>Atherosclerosis</i> , <b>2009</b> , 205, 506-11	3.1	28
79	Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. <i>Circulation</i> , <b>2009</b> , 120, 628-35	16.7	48
78	A novel mutation of the apolipoprotein A-I gene in a family with familial combined hyperlipidemia. <i>Atherosclerosis</i> , <b>2008</b> , 198, 145-51	3.1	9
77	Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2008</b> , 324, 776-83	4.7	51
76	The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential. <i>Journal of Lipid Research</i> , <b>2008</b> , 49, 954-60	6.3	46
75	ApoA-IMilano from structure to clinical application. <i>Annals of Medicine</i> , <b>2008</b> , 40, 48-56	1.5	3
74	Raising HDL cholesterol for cardiovascular disease prevention: Is this still feasible?. <i>Current Cardiovascular Risk Reports</i> , <b>2008</b> , 2, 35-40	0.9	
73	Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholestaemic response to simvastatin and fluvastatin. <i>Pharmacological Research</i> , <b>2007</b> , 55, 310-7	10.2	58
72	Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant. <i>Circulation</i> , <b>2007</b> , 116, 2165-72	16.7	38
71	A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 5125-32	5.4	59
70	Molecular characterization of two patients with severe LCAT deficiency. <i>Nephrology Dialysis Transplantation</i> , <b>2007</b> , 22, 2379-82	4.3	9
69	Apolipoprotein A-I breakdown is induced by thrombolysis in coronary patients. <i>Annals of Medicine</i> , <b>2007</b> , 39, 306-11	1.5	18
68	Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. <i>Journal of Lipid Research</i> , <b>2007</b> , 48, 592-9	6.3	135

67	Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. <i>Atherosclerosis</i> , <b>2007</b> , 195, 385-91	3.1	58
66	Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases. <i>Current Atherosclerosis Reports</i> , <b>2006</b> , 8, 163-7	6	42
65	Synthetic high density lipoproteins for the treatment of myocardial ischemia/reperfusion injury <b>2006</b> , 111, 836-54		16
64	LCAT deficiency: molecular genetics, lipid/lipoprotein phenotype and atherosclerosis. <i>Future Lipidology</i> , <b>2006</b> , 1, 241-245		2
63	High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease. <i>Expert Opinion on Therapeutic Targets</i> , <b>2006</b> , 10, 561-72	6.4	9
62	Japan: are statins still good for everybody?. <i>Lancet, The</i> , <b>2006</b> , 368, 1135-6	40	6
61	CETP levels rather than polymorphisms as markers of coronary risk: healthy athlete with high HDL-C and coronary disease--effectiveness of probucol. <i>Atherosclerosis</i> , <b>2006</b> , 186, 225-7	3.1	3
60	A model structure for the heterodimer apoA-IMilano-apoA-II supports its peculiar susceptibility to proteolysis. <i>Biophysical Journal</i> , <b>2006</b> , 91, 3043-9	2.9	12
59	Structure, function and amyloidogenic propensity of apolipoprotein A-I. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2006</b> , 13, 191-205	2.7	111
58	Inhibition of MMP-2 activation and release as a novel mechanism for HDL-induced cardioprotection. <i>FEBS Letters</i> , <b>2006</b> , 580, 5974-8	3.8	14
57	LCAT deficiency: molecular and phenotypic characterization of an Italian family. <i>Journal of Nephrology</i> , <b>2006</b> , 19, 375-81	4.8	8
56	Combined monogenic hypercholesterolemia and hypoalphalipoproteinemia caused by mutations in LDL-R and LCAT genes. <i>Atherosclerosis</i> , <b>2005</b> , 182, 153-9	3.1	15
55	High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2005</b> , 1736, 136-43	5	31
54	Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2005</b> , 15, 47-55	4.5	30
53	The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2005</b> , 25, 1972-8	9.4	136
52	Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 9930-6	5.4	103
51	Synthetic high-density lipoproteins exert cardioprotective effects in myocardial ischemia/reperfusion injury. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2004</b> , 308, 79-84	4.7	45
50	A 33-year-old man with nephrotic syndrome and lecithin-cholesterol acyltransferase (LCAT) deficiency. Description of two new mutations in the LCAT gene. <i>Nephrology Dialysis Transplantation</i> , <b>2004</b> , 19, 1622-4	4.3	9



49	Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. <i>Gastroenterology</i> , <b>2004</b> , 126, 1416-22	13.3	59
48	Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. <i>Pharmacological Research</i> , <b>2004</b> , 49, 493-9	10.2	33
47	An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. <i>Metabolism: Clinical and Experimental</i> , <b>2004</b> , 53, 153-8	12.7	106
46	Recurrent mutations of the apolipoprotein A-I gene in three kindreds with severe HDL deficiency. <i>Atherosclerosis</i> , <b>2003</b> , 167, 335-45	3.1	29
45	High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. <i>Circulation Research</i> , <b>2003</b> , 92, 330-7	15.7	133
44	Abnormal splicing of ABCA1 pre-mRNA in Tangier disease due to a IVS2 +5G>C mutation in ABCA1 gene. <i>Journal of Lipid Research</i> , <b>2003</b> , 44, 254-64	6.3	27
43	Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux. <i>Journal of Lipid Research</i> , <b>2003</b> , 44, 539-46	6.3	38
42	Endothelial protection by high-density lipoproteins: from bench to bedside. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2003</b> , 23, 1724-31	9.4	193
41	Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 4301-8	5.4	179
40	Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2002</b> , 22, 1475-81	9.4	46
39	Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2002</b> , 22, 656-61	9.4	98
38	Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini. <i>Biochemical Journal</i> , <b>2002</b> , 362, 627-34	3.8	21
37	Size is a major determinant of dissociation and denaturation behaviour of reconstituted high-density lipoproteins. <i>Biochemical Journal</i> , <b>2002</b> , 366, 245-53	3.8	11
36	Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini. <i>Biochemical Journal</i> , <b>2002</b> , 362, 627-634	3.8	32
35	The C-terminal domain of apolipoprotein A-I is involved in ABCA1-driven phospholipid and cholesterol efflux. <i>Biochemical and Biophysical Research Communications</i> , <b>2002</b> , 299, 801-5	3.4	24
34	Omega-3 fatty acid ethyl esters increase heart rate variability in patients with coronary disease. <i>Pharmacological Research</i> , <b>2002</b> , 45, 475	10.2	64
33	Increased carotid artery intima-media thickness in subjects with primary hypoalphalipoproteinemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2002</b> , 22, 317-22	9.4	27
32	The Low-HDL Syndrome: Epidemiology and Pathophysiology. <i>Medical Science Symposia Series</i> , <b>2002</b> , 103-108		

31	Hypocomplementemic type II membranoproliferative glomerulonephritis in a male patient with familial lecithin-cholesterol acyltransferase deficiency due to two different allelic mutations. <i>Nephron</i> , <b>2001</b> , 88, 268-72	3.3	10
30	Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. <i>Circulation</i> , <b>2001</b> , 103, 1949-54	16.7	287
29	Limited proteolysis of a disulfide-linked apoA-I dimer in reconstituted HDL. <i>Journal of Lipid Research</i> , <b>2001</b> , 42, 935-942	6.3	30
28	Cardiovascular risk changes after lipid lowering medications: are they predictable?. <i>Atherosclerosis</i> , <b>2000</b> , 152, 1-8	3.1	12
27	Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. <i>Atherosclerosis</i> , <b>2000</b> , 148, 387-96	3.1	88
26	Recombinant apolipoproteins for the treatment of vascular diseases. <i>Atherosclerosis</i> , <b>1999</b> , 142, 29-40	3.1	45
25	Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer. <i>Biochemistry</i> , <b>1999</b> , 38, 16307-14	3.2	53
24	Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1999</b> , 19, 1257-62	9.4	106
23	Evidence-based medicine criteria applied to hypolipidemic and antihypertensive drug trials: is drug efficacy always the same?. <i>Pharmacological Research</i> , <b>1998</b> , 37, 339-43	10.2	2
22	Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. <i>Atherosclerosis</i> , <b>1998</b> , 139, 77-82	3.1	56
21	High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein. <i>Current Opinion in Lipidology</i> , <b>1997</b> , 8, 219-24	4.4	46
20	Reconstituted high-density lipoproteins with a disulfide-linked apolipoprotein A-I dimer: evidence for restricted particle size heterogeneity. <i>Biochemistry</i> , <b>1997</b> , 36, 12428-33	3.2	56
19	Denaturation and self-association of apolipoprotein A-I investigated by electrophoretic techniques. <i>Biochemistry</i> , <b>1997</b> , 36, 7898-905	3.2	12
18	Activation of lecithin cholesterol acyltransferase by a disulfide-linked apolipoprotein A-I dimer. <i>Biochemical and Biophysical Research Communications</i> , <b>1997</b> , 232, 345-9	3.4	43
17	Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. <i>Biochemical and Biophysical Research Communications</i> , <b>1997</b> , 238, 61-5	3.4	140
16	Human apolipoprotein A-II inhibits the formation of pre-beta high density lipoproteins. <i>Lipids and Lipid Metabolism</i> , <b>1996</b> , 1304, 32-42		8
15	Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1995</b> , 15, 1819-28	9.4	147
14	Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. <i>Annals of Neurology</i> , <b>1995</b> , 37, 596-604	9.4	130

13	Drug control of reverse cholesterol transport <b>1994</b> , 61, 289-324		30
12	Apolipoprotein E epsilon 4 allele in Alzheimer@ disease and vascular dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>1994</b> , 5, 240-2	2.6	17
11	Apolipoprotein A-I conformation in discoidal particles: evidence for alternate structures. <i>Biochemistry</i> , <b>1993</b> , 32, 6477-84	3.2	78
10	Sex-Related Differences in the Phenotypic Expression of the Apolipoprotein A-IMilano Mutant <b>1993</b> , 267-277		
9	Tolerability of fibric acids. Comparative data and biochemical bases. <i>Pharmacological Research</i> , <b>1992</b> , 26, 243-60	10.2	18
8	Apolipoprotein A-II modulates HDL remodeling in plasma. <i>Lipids and Lipid Metabolism</i> , <b>1992</b> , 1124, 195-8		19
7	Omega-3 fatty acids selectively raise high-density lipoprotein 2 levels in healthy volunteers. <i>Metabolism: Clinical and Experimental</i> , <b>1991</b> , 40, 1283-6	12.7	23
6	Comparison of the lipoprotein and hemostatic changes after a triphasic and a monophasic low dose oral contraceptive in premenopausal middle-aged women. <i>Atherosclerosis</i> , <b>1990</b> , 84, 203-11	3.1	14
5	Apolipoprotein AIMilano. Partial lecithin:cholesterol acyltransferase deficiency due to low levels of a functional enzyme. <i>Lipids and Lipid Metabolism</i> , <b>1990</b> , 1043, 1-6		39
4	Changes in high-density lipoprotein subfraction distribution and increased cholesteryl ester transfer after probucol. <i>American Journal of Cardiology</i> , <b>1988</b> , 62, 73B-76B	3	28
3	Apheretic treatment of severe familial hypercholesterolemia: comparison of dextran sulfate cellulose and double membrane filtration methods for low density lipoprotein removal. <i>Atherosclerosis</i> , <b>1988</b> , 73, 197-202	3.1	22
2	Alterations in the HDL system after rapid plasma cholesterol reduction by LDL-apheresis. <i>Metabolism: Clinical and Experimental</i> , <b>1988</b> , 37, 752-7	12.7	12
1	Endothelial Protection by High-Density Lipoproteins375-398		0